Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycemia and hormonal responses in metformin-treated type 2 diabetes.
DPP-4 inhibition has effects on both fasting and post-prandial glucose. However, the extent of this effect over the whole day and whether different DPP-4 inhibitors have the same effects have not been established. We, therefore, explored the whole day effects of three different DPP-4 inhibitors versus placebo on glucose, islet and incretin hormones after ingestion of breakfast, lunch and dinner in subjects with metformin-treated and well-controlled type 2 diabetes. The study was single-center and crossover designed, involving twenty-four subjects (twelve males, twelve females, mean age 63 yrs, BMI 31.0 kg/m2 , HbA1c 44.7 mmol/mol = 6.2%), who underwent four test days in random order. Each whole day test included ingestion of standardized breakfast (525kcal), lunch (780kcal), and dinner (560kcal) after intake of either sitagliptin (100mg), vildagliptin (50mg b.i.d), saxagliptin (5mg) or placebo. Compared to placebo, DPP-4 inhibition reduced glucose levels, increased beta-cell function (insulin secretory rate in relation to glucose), suppressed glucagon, increased intact GLP-1 and GIP but suppressed total GLP-1 and GIP after all three meals. The effects were sustained throughout the daytime period with similar changes after each meal and did not differ between the DPP-4 inhibitors. DPP-4 inhibition has persistent daytime effects on glucose, islet and incretin hormones with no difference between three different DPP-4 inhibitors. This article is protected by copyright. All rights reserved.